September 21, 2006 – Hospira will pay $2 billion to acquire Mayne Pharma of Australia; Serono accepted a $13.3 buyout offer from Germany-based Merck; Pozen received the $40 million upfront payment from its collaboration with AstraZeneca; Zelos and Nektar began a Phase I trial of an inhaled osteoporosis drug; Advanced Cell Technology used stem cells to restore visual function in rats; OSI Pharma began a Phase III trial of Tarceva as first-line therapy for lung cancer; Idenix won Swiss approval of telbivudine for chronic hepatitis B; BioMarin completed enrolling patients in a hypertension drug trial; and Biogen Idec and Alnylam will collaborate to discover RNAi therapeutics to treat PML. The Centient Biotech 200™ was up a fraction of a point at 3744.37, a gain of .02%. More details...
